Publications

Broadly neutralizing antibodies have been proposed as templates for HIV-1 vaccine design, but it has been unclear how similar vaccine-elicited antibodies are to their naturally elicited templates. To provide insight, here we compare the recognition of naturally elicited and vaccine-elicited antibodies targeting the HIV-1 fusion peptide, which comprises envelope (Env) residues 512–526, with the most common sequence being AVGIGAVFLGFLGAA. Naturally elicited antibodies bound peptides with substitutions to negatively charged amino acids at residue positions 517–520 substantially better than the most common sequence, despite these substitutions rarely appearing in HIV-1; by contrast, vaccine-elicited antibodies were less tolerant of sequence variation, with no substitution of residues 512–516 showing increased binding. Molecular dynamics analysis and cryo-EM structural analysis of the naturally elicited ACS202 antibody in complex with the HIV-1 Env trimer with an alanine 517 to glutamine substitution suggested enhanced binding to result from electrostatic interactions with positively charged antibody residues. Overall, vaccine-elicited antibodies appeared to be more fully optimized to bind the most common fusion peptide sequence, perhaps reflecting the immunization with fusion peptide of the vaccine-elicited antibodies.

African swine fever (ASF) is an acute, highly contagious and deadly infectious disease. It is a threat to animal health with major potential economic and societal impact. Despite decades of ASF vaccine research, still some gaps in knowledge are hindering the development of a functional vaccine. Worth mentioning are gaps in understanding the mechanism of ASF infection and immunity, as well as the fact that – in case of this disease – virus proteins, so-called protective antigens, responsible for inducing protective immune responses in pigs are not identified yet. In this paper we elaborate on a methodology to identify protective antigens based on epitope mapping by microarray technology. High density peptide microarrays, combined with fluorescence scanning, have been used to analyze the interaction of peptide sequences of African swine fever virus (ASFV) proteins with antibodies present in inactivated serum from infected and healthy animals. The study evidenced ASFV proteins already under the radar for vaccine development, such as p54, and identified specific sequences in those proteins that may become the focus for future vaccine candidates. Such methodology is amenable to automation and high-throughput and may help developing better targeting for next generation vaccines.

Abstract Background We have previously isolated a highly mutated (83% homologous to predicted heavy chain germline) antibody (Ab) termed C group 76-Q13-6F5 (6F5) that targets a conformational epitope on gp41. 6F5, though non-neutralizing, has the capacity to mediate Ab dependent cell cytotoxicity (ADCC). When the variable chain (predicted to be VH1-02 derived) was mutated to germline (termed C group 76 ancestor, or 76Canc), surprisingly this Ab still exhibited significant ADCC activity. Many HIV vaccine strategies are focused on raising highly mutated Abs. We propose that there would be an advantage to developing vaccines related to epitopes that permit functional targeting by Abs using germline variable gene sequences. Methods To explore potential protein targets for vaccination strategies to raise and develop such Abs, we interrogated a peptide array of 29,127 linear peptides using PEPperCHIP® Human Epitome Microarray. We then confirmed peptide binding by Western blot and ELISAs. We also assessed binding to CDI laboratories HuProt protein microarray, containing > 21,000 human proteins. Results 76Canc specifically recognized a number of peptides enriched for glutamic and aspartic acid residues (top hit DEEEEYDEDEYEYDE). Meme analysis of positive peptides revealed a peptide sequence most similar to Hepatitis C virus, similar to a peptide implicated in Kawasaki disease (KD). We confirmed specific binding of four of the top peptide hits, including hepatitis C peptide recognition. We then confirmed binding of 76Canc-related Abs to a published optimized KD related peptide (KPAVIPDREALYQDIDEMEEC). Serum from KD and infectious controls was used to compete with biotinylated 76Canc-related Abs. Serum Abs targeting this epitope showed no specific correlation to having KD. Autoantigen screening of 76Canc identified a single human protein of interest that did contain acidic amino acid rich regions.Figure 1:HIV-1 gp41 antibodies recognize peptides similar to peptide implicated in Kawasaki Disease Conclusion This study reveals acidic motif targeting by specific anti-gp41 Abs and the derived germline Ab, but no evidence that these Abs are related to inflammation similar to KD. Cautious development of targeting such Abs by vaccination is warranted. Future structural comparison of these peptides with native proteins and binding competition studies are needed to confirm mimotope binding. Disclosures Mark D. Hicar, MD/PhD, Pfizer: site investigator for 2 trial

Abstract The threat of spillovers of coronaviruses associated with the severe acute respiratory syndrome (SARS) from animals to humans necessitates vaccines that offer broader protection from sarbecoviruses. By leveraging a viral-genome-informed computational method for selecting immune-optimized and structurally engineered antigens, here we show that a single antigen based on the receptor binding domain of the spike protein of sarbecoviruses elicits broad humoral responses against SARS-CoV-1, SARS-CoV-2, WIV16 and RaTG13 in mice, rabbits and guinea pigs. When administered as a DNA immunogen or by a vector based on a modified vaccinia virus Ankara, the optimized antigen induced vaccine protection from the Delta variant of SARS-CoV-2 in mice genetically engineered to express angiotensin-converting enzyme 2 and primed by a viral-vector vaccine (AZD1222) against SARS-CoV-2. A vaccine formulation incorporating mRNA coding for the optimized antigen further validated its broad immunogenicity. Vaccines that elicit broad immune responses across subgroups of coronaviruses may counteract the threat of zoonotic spillovers of betacoronaviruses.